MAZE
Maze Therapeutics, Inc. NASDAQ$26.93
Mkt Cap $1.5B
52w Low $8.24
41.2% of range
52w High $53.65
50d MA $36.89
200d MA $32.07
P/E (TTM)
-8.9x
EV/EBITDA
-11.5x
P/B
3.3x
Debt/Equity
0.1x
ROE
-36.9%
P/FCF
-15.8x
RSI (14)
—
ATR (14)
—
Beta
5.16
50d MA
$36.89
200d MA
$32.07
Avg Volume
873.0K
About
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of renal, cardiovascular, related metabolic diseases, and obesity in the United States. Its lead programs includes MZE829, an oral small molecule inhibitor of apolipoprotein L1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | 1M% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 25, 2026 | AMC | -0.73 | -0.65 | +11.0% | 31.73 | -2.0% | -0.1% | -4.3% | -8.6% | -5.9% | -8.4% | -18.7% | — |
| Nov 6, 2025 | AMC | -0.74 | -0.66 | +10.8% | 29.63 | +0.8% | -3.5% | +2.9% | +8.9% | +9.9% | +7.5% | +39.9% | — |
| Aug 12, 2025 | AMC | -0.79 | -0.77 | +2.5% | 13.74 | +1.9% | -1.0% | -2.8% | -1.7% | -2.8% | -2.1% | +80.5% | — |
| May 14, 2025 | AMC | -0.76 | -1.15 | -51.3% | 9.06 | -2.5% | +2.1% | +2.1% | +7.1% | +11.6% | +16.1% | +47.9% | — |
| Mar 31, 2025 | AMC | 0.45 | -18.32 | -4171.1% | 11.01 | -2.8% | -10.1% | -5.8% | -15.3% | -17.6% | -19.0% | -16.0% | — |
| Sep 30, 2024 | AMC | — | -0.57 | — | — | — | — | — | — | — | — | — | — |
| Jun 30, 2024 | AMC | — | 3.18 | — | — | — | — | — | — | — | — | — | — |
| Mar 31, 2024 | AMC | — | -0.74 | — | — | — | — | — | — | — | — | — | — |
| Dec 31, 2023 | AMC | — | -0.61 | — | — | — | — | — | — | — | — | — | — |
| Sep 30, 2023 | AMC | — | -0.57 | — | — | — | — | — | — | — | — | — | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 14 | Truist | Maintains | Buy → Buy | — | $27.42 | $27.66 | +0.9% | +0.9% | -2.1% | -2.0% | +2.4% | -2.1% |
| Mar 31 | JP Morgan | Maintains | Overweight → Overweight | — | $29.01 | $29.50 | +1.7% | +2.9% | +0.1% | -1.0% | -0.0% | -2.3% |
| Mar 25 | BTIG | Maintains | Buy → Buy | — | $49.00 | $40.00 | -18.4% | -35.2% | -35.3% | -38.0% | -40.8% | -39.1% |
| Mar 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $49.00 | $40.00 | -18.4% | -35.2% | -35.3% | -38.0% | -40.8% | -39.1% |
| Mar 16 | Wedbush | Maintains | Outperform → Outperform | — | $50.21 | $50.96 | +1.5% | +2.1% | +0.4% | -3.5% | -1.6% | -4.3% |
| Mar 9 | BTIG | Maintains | Buy → Buy | — | $44.83 | $44.00 | -1.9% | +0.5% | +13.9% | +12.5% | +15.6% | +12.0% |
| Mar 4 | Guggenheim | Maintains | Buy → Buy | — | $44.18 | $46.59 | +5.5% | +5.2% | +2.5% | +1.5% | +2.0% | +15.6% |
| Jan 16 | BTIG | Maintains | Buy → Buy | — | $39.81 | $39.84 | +0.1% | +2.4% | +11.4% | +9.8% | +16.1% | +11.2% |
| Dec 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $37.27 | $37.89 | +1.7% | +11.3% | +14.3% | +11.9% | +11.2% | +9.4% |
| Nov 7 | Wedbush | Maintains | Outperform → Outperform | — | $29.63 | $29.87 | +0.8% | -3.5% | +2.9% | +8.9% | +9.9% | +7.5% |
Recent Filings
8-K · 8.01
!! High
Maze Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
Maze Therapeutics is conducting a public offering of shares at $23.50 per share and pre-funded warrants at $23.499, providing investors with immediate equity exposure and minimal-cost warrant exercise options.
Apr 22
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
Kumar's departure as CEO of BridgeBio Oncology signals potential leadership instability at the oncology subsidiary, which could impact clinical trial progress and investor confidence in the parent company's pipeline.
Mar 25
8-K · 1.01
!! High
Maze Therapeutics, Inc. -- 8-K 1.01: Material Agreement
Maze Therapeutics secured $40 million in initial term loan funding from Hercules Capital, providing capital for operations and development while obligating the company to repay debt.
Feb 4
Data updated apr 25, 2026 8:42pm
· Source: massive.com